Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesStocksEarnInstitutionAI & More
TD Synnex Earnings Seen Reigniting Momentum as Hyve Growth Accelerates, Morgan Stanley Says

TD Synnex Earnings Seen Reigniting Momentum as Hyve Growth Accelerates, Morgan Stanley Says

MT newswireMT newswire2026/09/15 15:08
11:08 AM EDT, 09/15/2026 (MT Newswires) -- TD Synnex's (SNX) fiscal Q3 earnings should help the stock regain momentum on strength in its Hyve hyperscale-infrastructure business and improving operating margins, Morgan Stanley said Tuesday in a report. TD Synnex has lagged behind the Standard & Poor's 500 in the past three months despite reporting a May quarter in which revenue rose 31% from a year earlier and EPS climbed 62%, the report said. Morgan Stanley attributed the underperformance partly to weakening sentiment around Hyve, which designs and builds data-center hardware for major cloud providers. Morgan Stanley expects a strong August-quarter beat and a November-quarter raise, with its EPS estimates about 7% above consensus amid resilient enterprise hardware spending, robust Hyve growth and solid margin expansion. The market continues to undervalue TD Synnex's medium-term earnings power, driven partly by distribution share gains and a reaccelerating Hyve business, the report said. Morgan Stanley forecasts fiscal 2028 EPS of $31.45, 30% above Wall Street estimates. The company is scheduled to report results on Sept. 24. Morgan Stanley cut its price target on TD Synnex stock to $334 from $374 and maintained its overweight rating. Price: 264.20, Change: +3.08, Percent Change: +1.18
0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

GlaxoSmithKline endorses: anti-inflammatory biotech company Rezera (RZRA.US) plans to raise $200 millions through IPO, with a valuation of $254 millions

Rezera plans to raise $200 million in its IPO on Nasdaq, with an offering price between $11 and $13. GSK intends to subscribe for up to $25 million. The mid-point valuation is $254 million, and the company focuses on oral NLRP3 inhibitors.

智通财经•2026/11/06 07:56

Anthropic (ANT.US) to launch IPO roadshow next week, valuation may shrink from 1.5 trillion dollars to 1 trillion dollars! The AI capital feast faces a test.

After the AI sell-off, major investors are questioning whether Anthropic can go public at a $1.5 trillion valuation, or if it will be reduced to around $1 trillion. Fundraising may also decrease from $100 billion to $80 billion.

智通财经•2026/11/06 07:53

Hong Kong live music service provider Guitar Group applies for US IPO, aiming to raise $31 million

Guitar Group, a provider of music performance events, guitar-making workshops, and guitar repair services, submitted an application to the U.S. Securities and Exchange Commission (SEC) on Thursday, seeking to raise up to $31 million through an initial public offering (IPO).

智通财经•2026/11/06 07:50